Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Cash & Equivalents (2016 - 2025)

Bioceres Crop Solutions' Cash & Equivalents history spans 6 years, with the latest figure at $48.1 million for Q2 2023.

  • For Q2 2023, Cash & Equivalents rose 43.78% year-over-year to $48.1 million; the TTM value through Jun 2023 reached $48.1 million, up 43.78%, while the annual FY2023 figure was $48.1 million, 43.78% up from the prior year.
  • Cash & Equivalents for Q2 2023 was $48.1 million at Bioceres Crop Solutions, up from $33.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $48.1 million in Q2 2023 and bottomed at $3.5 million in Q2 2019.
  • The 5-year median for Cash & Equivalents is $36.0 million (2021), against an average of $32.7 million.
  • The largest annual shift saw Cash & Equivalents soared 1132.23% in 2020 before it decreased 15.23% in 2021.
  • A 5-year view of Cash & Equivalents shows it stood at $3.5 million in 2019, then skyrocketed by 1132.23% to $42.5 million in 2020, then dropped by 15.23% to $36.0 million in 2021, then decreased by 7.13% to $33.5 million in 2022, then soared by 43.78% to $48.1 million in 2023.
  • Per Business Quant, the three most recent readings for BIOX's Cash & Equivalents are $48.1 million (Q2 2023), $33.5 million (Q2 2022), and $36.0 million (Q2 2021).